|
|
||||||||
1 Department of Physiology and Pharmacology, School of Medicine, Loma Linda University, Loma Linda 92350; and 2 Department of Pharmacology, College of Medicine, University of California, Irvine, California 92697
| |
ABSTRACT |
|---|
|
|
|---|
In addition to adrenergic
innervation, cerebral arteries also contain neuronal nitric oxide
synthase (nNOS)-expressing nerves that augment adrenergic nerve
function. We examined the impact of development and chronic
high-altitude hypoxia (3,820 m) on nNOS nerve function in near-term
fetal and adult sheep middle cerebral arteries (MCA). Electrical
stimulation-evoked release of norepinephrine (NE) was measured with
HPLC and electrochemical detection, whereas nitric oxide (NO) release
was measured by chemiluminescence. An inhibitor of NO synthase,
N
-nitro-L-arginine methyl ester
(L-NAME), significantly inhibited stimulation-evoked NE
release in MCA from normoxic fetal and adult sheep with no effect in
MCA from hypoxic animals. Addition of the NO donor
S-nitroso-N-acetyl-DL-penicillamine
fully reversed the effect of L-NAME in MCA from normoxic
animals with no effect in MCA from hypoxic animals. Electrical
stimulation caused a significant increase in NO release in MCA from
normoxic animals, an effect that was blocked by the neurotoxin
tetrodotoxin, whereas there was no increase in NO release in MCA from
hypoxic animals. Relative abundance of nNOS as measured by
Western blot analysis was similar in normoxic fetal and adult MCA.
However, after hypoxic acclimitization, nNOS levels dramatically
declined in both fetal and adult MCA. These data suggest that the
function of nNOS nerves declines during chronic high-altitude hypoxia,
a functional change that may be related to a decline in nNOS protein levels.
high-altitude hypoxemia; cerebrovascular circulation; neuronal nitric oxide synthase nerves; development and sympathetic nerve function; recombinant neuronal nitric oxide synthase; norepinephrine release
| |
INTRODUCTION |
|---|
|
|
|---|
ALTHOUGH THE CEREBRAL VASCULATURE is well innervated by sympathetic nerves, their contribution to the control of cerebral blood flow under normal physiological conditions is unclear (1, 4, 5). Variations in blood pressure elicit autoregulatory adjustments of arterial diameter, maintaining constant cerebral blood flow (5). When arterial pressure is elevated (150-180 mmHg), reflex sympathetic nerve activation blunts increases in cerebral blood flow and reduces the risk of blood-brain barrier disruption (6, 15). Thus sympathetic nerves have been suggested to protect an organism from various stresses such as severe hypertension or hypercapnia (5, 11). The development of elevated arterial pressure in fetal sheep at high altitude has been noted (21). However, cerebral blood flow did not increase in the face of arterial hypertension. It is possible that adrenergic innervation may play an important role in protecting the fetal cerebral circulation at high altitude (21).
In addition to sympathetic nerves, cerebral blood vessels are innervated by nerves that contain neuronal nitric oxide synthase (nNOS) and release nitric oxide (NO) (18, 33). In dog middle cerebral artery (MCA) strips denuded of endothelium, relaxation induced by transmural nerve stimulation (TNS) or nicotine is blocked either by NOS antagonists or by the neuronal poison TTX (32, 33). Thus, in cerebral arteries, NO is liberated during nerve stimulation. In perfused sheep MCAs, TNS increases the overflow of both norepinephrine (NE) and NO. In contrast, in the facial artery TNS increases overflow of NE but not NO (24). These studies suggest that NE and NO are simultaneously released with nerve activation in the cerebrovasculature.
Immunohistochemical techniques have identified structural apposition
between adrenergic and nNOS neurons in both the porcine cerebrovasculature and rat superior cervical ganglion (10, 19, 29, 35, 39). Furthermore, nicotine relaxes constricted basilar artery strips, an effect abolished by adrenergic denervation
(39). Blockade of
2-adrenoceptors
antagonizes nicotine-induced relaxation in the same artery model
(19). Overall, these data suggest that the release of NE
subsequently activates adjacent nNOS nerves, and adrenergic
nerves are necessary for the normal function of nNOS nerves in cerebral arteries.
The release of NO from nNOS nerves has been shown to augment stimulation-evoked NE release. In rat cerebral cortex, N-methyl-D-aspartate or K+-evoked NE release from hippocampal slices is blocked by NOS antagonists (23, 25). Consistent with these studies, NOS antagonists have been shown to inhibit NE release in sheep MCAs (4, 24).
Little is known about the physiological role of the interaction between nNOS-containing and adrenergic nerves. As mentioned above, adrenergic innervation of cerebral vessels is thought to be particularly important during cardiovascular stresses such as hypertension. Our laboratory has had a long-term interest in the impact of chronic high-altitude hypoxia on the function of the cerebral circulation of both the fetus and adult (3, 4, 20, 21). Therefore, we used this model of chronic high-altitude hypoxemia in the pregnant ewe to investigate the functional relation between endogenous nNOS and adrenergic nerves in cerebral arteries. We compared stimulation-evoked NE and NO release in the MCAs from normoxic and hypoxic near-term fetal and adult sheep. The facial artery was used for comparison because it lacks nNOS-containing nerves (4, 24). In addition, we quantified the relative abundance of nNOS in cerebral blood vessel homogenates by using Western blot analysis. Two hypotheses were addressed: 1) ability of nNOS nerves to modulate adrenergic transmitter release will be altered by high-altitude acclimatization in an age-dependent manner, and 2) high-altitude acclimatization will alter nNOS abundance in cerebral arteries.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Forty pregnant and forty nonpregnant ewes of mixed breed were obtained from one supplier (Nebeker Ranch, Lancaster, CA). These animals were randomly separated into two groups: control normoxic (20 pregnant and 20 nonpregnant) and long-term hypoxic (20 pregnant and 20 nonpregnant). Animals in the hypoxic group were transferred to the White Mountain Research Station (Bishop, CA; altitude of 3,280 m) where they were maintained for ~100 days. Ewes in the normoxic group remained at Nebeker ranch (718 m). All pregnant animals were studied at 138-142 days of gestation. At the appropriate time, hypoxic animals were transported to the Department of Perinatal Biology at Loma Linda University where they underwent immediate study. In the hypoxic ewes, nonocclusive tracheal catheters were surgically implanted (14) to allow the administration of N2 gas. This procedure maintained the arterial PO2 at ~60 Torr. Arterial PO2 in the adults was measured in 0.5-ml blood samples (ABL300, Radiometer, Copenhagen, Denmark). The mean PO2 for normoxic adults was 100 ± 2 Torr and for hypoxic adults was 60 ± 3 Torr. Mean PO2 value for normoxic fetuses was 23 ± 1 Torr and for hypoxic fetuses was 19 ± 0.7 Torr. On the day of the experiment, ewes were euthanized by an intravenous injection of pentobarbital sodium (100 mg/kg), and the fetuses were delivered by cesarean section. Fetal weights were not significantly affected by hypoxia and averaged 4,409 ± 263 g for hypoxic and 4,263 ± 138 g for normoxic animals. After death, facial arteries and brains were removed from adults and fetuses and immediately placed in separate beakers containing ice-cold Krebs solution. Dissection of MCAs followed. The Krebs solution contained (in mM) 118 NaCl, 4.8 KCl, 1.6 CaCl2, 1.2 KH2PO4, 25 NaHCO3, 1.2 MgSO4, 0.3 ascorbic acid, and 11.5 glucose.
Tissue preparation. Three- to four-centimeter lengths of the MCAs and the comparison tissue, the facial artery, were cannulated at both ends and mounted on a low-volume perfusion system as previously described (2). The MCA segment used was the main branch from the circle of Willis. The diameters of the MCAs and facial arteries ranged from 0.8 to 1.0 mm and from 1.0 to 1.4 mm, respectively. Arteries were perfused at a rate of 1 ml/min with aerated (95% O2-5% CO2) Krebs at a perfusion pressure of ~60-70 mmHg in either artery type. The entire assembly was immersed in a circulating water bath kept at 37°C. In all experiments, a Grass model S-48 stimulator (Grass Instruments, Quincy, MA) delivered electrical field stimulation to perivascular nerves through a pair of platinum electrodes. The stimulation parameters were 8 Hz, 60 V (supermaximal voltage), 1-ms duration, and 480 pulses (1-min stimulation). We measured voltage and current delivery to the platinum electrodes in each tissue bath before and during each experiment with an ohmmeter-ammeter (Wavetek, San Diego, CA). This was done to ensure that equivalent current and voltage were being delivered to each set of electrodes in each bath.
Simultaneous assay of NE and NO release.
To simultaneously measure NE and NO release, nerves were first
activated (S1) for 1 min followed by a 45-min equilibration. Tissues were then exposed for 30 min to the neuronal toxin TTX (1 µM), to verify the neurogenic origin of stimulation-evoked release of
NE and NO, and nerves were activated again (S2) for 1 min. The
perfusates were collected during the stimulation until 5 ml were
collected (~5 min). A 900-µl aliquot was immediately frozen in
liquid N2 and stored at
80°C until NO analysis was performed. The remaining 4.1 ml of the sample were assayed for NE.
Tissues were exposed throughout the experiment to deoxycorticosterone and cocaine (10
5 M) to block extraneuronal and neuronal
uptake of NE, respectively. A 5-ml sample was collected before each
nerve activation to enable monitoring of basal NE and NO release.
Effect of N
-nitro-L-arginine methyl
ester and S-nitroso-N-acetyl-DL-penicillamine on
stimulation-evoked NE release.
This protocol was designed to test the effects of NOS inhibition with
L-NAME on NE release. Perivascular nerves in the control normoxic and hypoxic arteries were activated three consecutive times
(S1-S3) for 1 min with a 45-min rest between stimulations. These
time controls were used to establish the consistency of NE release over
the experimental time course. In treatment tissues, perivascular nerves
were activated once for 1-min (S1) and then equilibrated for 45 min in
buffer containing 10 µM
N
-nitro-L-arginine methyl ester
(L-NAME). The tissues were again activated for 1 min (S2)
followed by another 45-min equilibration period where tissues were
exposed to buffer containing 10 µM L-NAME and the NO
donor
S-nitroso-N-acetyl-DL-penicillamine
(SNAP), and again the nerves were activated for 1 min (S3). Control and
treatment tissues were exposed throughout the experiment to
deoxycorticosterone and cocaine (10
5 M) to block
extraneuronal and neuronal uptake of NE, respectively. Basal NE release
was monitored by taking a 5-ml sample before each nerve activation in
both time control and treatment arteries.
Measurement of NE.
In each perfusate sample, NE was extracted with alumina at pH 8.6. The
internal standard 3,4-dihydroxybenzylamine (DHBA; 400 pg) was then
added by using a protocol described previously
(2). A 100-µl sample of the extracted amines was
injected into an ESA Coulochem II high-performance liquid chromatograph
(ESA, Bedford, MA) and separated on an ESA reverse-phase
C18 column. The ESA MD-TM eluting mobile phase contained 75 mM Na2H2PO4, 0.5 M sodium dodecyl
sulfate, 0.025 mM EDTA, 20% acetonitrile, and 5% methanol. The amount
of NE in the injected samples was calculated with the following
equation
|
(1) |
|
(2) |
Measurement of NO. NO was measured with the Seiver 280B NO analyzer. Before the measurement of NO in the samples, a series of standard NaNO3 solutions were run from which a standard curve was obtained. Frozen samples of perfusate were thawed, and NO was measured as previously described (36). In brief, NO was measured by injection of a 100-µl aliquot of the perfusate into a Sievers 280B NO analyzer (Sievers Instruments, Boulder, CO). In this instrument, stable nitrates and nitrites are reduced to NO. NO is then measured by reaction with ozone, which yields photons detected by a photomultiplier tube. Calibration curves were run during each analysis, and individual standard curves (0-200 pmol) were used to convert NO signals from samples into picomoles of NOx.
Isolation of soluble protein in cerebral blood vessels. Cerebral artery homogenates were prepared as previously described (26). Briefly, cerebral arteries were dissected from two to three brains and were weighed, pooled and homogenized in 1 ml of ice-cold N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (50 mM, pH 7.0). Facial arteries were also pooled and prepared in the same manner as cerebral arteries. Homogenates were centrifuged for 30 min at 10,000 g. The supernatant was decanted and centrifuged for 75 min at 180,000 g. Total tissue soluble-protein content was calculated from spectrophotometric measurements of soluble protein in a 10-µl aliquot of the 180,000-g supernatant by using a bicinchoninic acid protein assay kit and bovine serum albumin standard obtained from Pierce (Rockford Il) (30).
Western blot analysis.
Western immunoblotting techniques were used to detect and quantify the
relative levels of nNOS in cerebral artery homogenates from fetal and
adult normoxic and hypoxic sheep (34). Soluble protein
samples and recombinant rat nNOS (brain cell NOS) standards (Biomol,
Plymouth Meeting, PA) were prepared in Laemmli buffer (Bio-Rad,
Hercules, CA) containing 5% 2-mercaptoethanol. Samples and
standards were heated to 100°C for 5 min, separated by 7.5% Tris · HCl sodium dodecyl-sulfate polyacrylamide
gels (150 V, 90 min), and transferred onto polyvinyldiene difluoride
membranes with a semidry transfer cell (15 V, 55 min, Bio-Rad).
Completion of electroblotting of samples and nNOS standards was
verified by staining the gel overnight with Coommasie blue. After
blotting was completed, gels consistently stained negative for protein bands, demonstrating complete protein transfer. Membranes were blocked
for 12 h (14 h maximum) at 4°C in blocking buffer containing 10 mM Tris · HCl (pH 7.5), 100 mM NaCl, 0.1% Tween
20, and 6% nonfat dry milk. The blocking buffer was replaced with
fresh blocking buffer containing rabbit anti-rat polyclonal nNOS IgG
antibody (Biomol) diluted 1:1,000 and then incubated for 1 h.
Membranes were washed three times (20 min each) with buffer containing
10 mM Tris · HCl, 2 mM NaCl, and 0.1% Tween 20 and incubated for 1 h in washing buffer containing 6% nonfat dry
milk and secondary alkaline phosphatase-conjugated antibody (1:1,000
dilution, Bio-Rad). Membranes were again washed three times, 20 min
each, and protein bands were detected by enhanced chemiluminescence and
exposed to film (Amersham Pharmacia Biotech, Newark, NJ). On each gel, a molecular weight ladder (Bio-Rad) was used to confirm the relative molecular weight of nNOS in samples and nNOS recombinant standards. Sample and recombinant nNOS standards consistently yielded a single band migrating between the molecular weight ladder standards of myosin
(199) and
-galactosidase (128).
The approximate molecular mass of 155 kDa in this single-sample band
corresponded to the molecular weight of the rat nNOS recombinant
standard (34).
Quantification of the relative abundance of nNOS. Densitometric analysis of autoradiographic films was used to determine relative abundance of nNOS in cerebral artery homogenates. Plots of optical density vs. nanograms of recombinant nNOS for each Western blot were used as a standard curve to quantify the relative amount of nNOS in each sample. Standard curves were linear from 4 to 30 ng of recombinant nNOS standard with a lower limit of detection of 2.5 ng. A linear equation (r = 0.996) was used to convert the optical density of nNOS bands in the samples to nanograms of nNOS. Relative abundance was determined simply by the ratio of nanograms nNOS detected in sample to micrograms of total soluble protein.
Statistical analysis. Two-way ANOVA and Fisher's protected least significant difference test were used to analyze the impact of development and chronic hypoxia on NE content, abundance of nNOS, and stimulation-evoked NE and NO release. All data were analyzed for heterogeneity of variance by Cochran's test. If significant heterogeneity was detected, then the data were transformed to log values and the tests repeated. The effects of L-NAME and SNAP treatment on stimulation-evoked NE release relative to controls within the groups were determined by paired Student's t-test. Comparison of stimulation-evoked NE and NO release to basal overflow and the effect of TTX were also determined by paired t-test. In this study, a value of P < 0.05 was considered to be statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Stimulation-evoked NE and NO release in normoxic MCAs.
Activation of perivascular nerves in fetal and adult normoxic MCAs
significantly increased fractional NE release (Fig. 1, A and
B). In the same tissues,
activation of perivascular nerves significantly increased NO overflow
compared with basal release (Fig. 1, C And D).
The neurotoxin TTX completely blocked stimulation-evoked NE and NO
release, confirming a neuronal source for both NE and NO. Activation of
perivascular nerves in fetal and adult normoxic facial arteries also
significantly increased fractional NE release, and this increase was
blocked with TTX (data not shown). However, in contrast to results with
MCAs, in the facial artery there was no increase in NO overflow during
nerve stimulation, as we have previously shown (24). TTX
also had no effect on no overflow in the facial artery.
|
Effects of development and chronic hypoxia on stimulation-evoked NE
release.
Effects of the NOS antagonist L-NAME and the NO donor SNAP
on stimulation-evoked fractional NE release from normoxic fetal and
adult MCAs are shown in Fig. 2. To
validate the effects of L-NAME and SNAP, time controls were
used to ensure that stimulation-evoked NE release from adrenergic
nerves was consistent over the experimental time course.
Stimulation-evoked NE release in these time controls was consistent for
both normoxic and hypoxic fetal and adult arteries (Table
1). In the presence of
L-NAME, stimulation-evoked NE release significantly
declined in normoxic fetal and adult MCAs. This effect was completely
reversed by application of the NO donor SNAP (Fig. 2, A and
B). In contrast, in MCAs from hypoxic fetal or adult
animals, L-NAME and SNAP no longer had any effect on stimulation-evoked NE release (Fig. 2, C and D).
In the facial artery, L-NAME had no significant effect on
stimulation-evoked NE release from either normoxic or hypoxic fetal and
adult animals (Table 2).
|
|
|
Effect of development and chronic hypoxia on nNOS levels.
As shown in Fig. 3, A
and C, soluble nNOS was detected in supernatants isolated
from normoxic fetal and adult cerebral artery homogenates. There was no
detectable nNOS in the pellet fraction, confirming that the
homogenization method we employed efficiently extracted all nNOS into
the soluble aqueous phase (Fig. 3, A-D). Interestingly, nNOS levels were significantly lower in supernatants from hypoxic than from normoxic homogenates, regardless of age (Fig. 3,
B and D). In contrast to the MCAs, there was no
detectable nNOS in supernatant or pellet fractions from normoxic or
hypoxic fetal and adult facial arteries (data not shown).
|
|
NE content and basal NE release.
Table 3 summarizes NE content in MCAs
from fetal and adult normoxic and hypoxic sheep. NE content in
the MCAs of normoxic and hypoxic fetal sheep was significantly lower
compared with the MCAs from both the normoxic and hypoxic adult. NE
content was depressed in MCAs from both fetal and adult sheep
acclimatized to chronic hypoxia, although this effect reached
statistical significance only in adult animals.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The most interesting result of this study is that, in cerebral arteries from adult and fetal sheep, chronic hypoxia causes a loss of stimulation-evoked NO release and a concomitant decline in nNOS levels. To our knowledge, this is the first time that a substantial loss of function of NOS-containing nerves in the cerebral circulation has been demonstrated after high-altitude hypoxia. Despite the hypoxic-induced loss of nNOS nerve function that normally augments NE release, stimulation-evoked NE release was not significantly different in arteries from normoxic and hypoxic animals. These results underscore the adaptive potential of the cerebral circulation during moderate, chronic high-altitude hypoxia. Our laboratory's previous studies have shown that during high-altitude hypoxia, blood pressure rises both in the fetus and adult (21). The present results further suggest that hypoxia induced attenuation of the function of nNOS nerves contributes to the pressor effects of altitude acclimatization.
Model of chronic hypoxia in adult and fetus. Adaptation to physiological stresses such as chronic hypoxia involves the sympathetic nervous system (5, 28). Stress imposed by chronic hypoxia can be particularly intense in fetal mammals confined to a lowered O2 tension environment. To compensate for this O2 deficit, normoxic mammalian fetuses exhibit high cardiac output and O2 delivery (22). In this study, pregnant sheep were maintained at 3,820 m, resulting in moderate maternal and fetal hypoxia, well in the range of successful adaptation in sheep. Whereas the compensatory cardiovascular, pulmonary, and hematological consequences of high-altitude hypoxemia are well defined (17), there appears to be a "threshold" of O2 deprivation, which, if exceeded, leads to pathological consequences (21). During ovine gestation at 3,820 m, adult and fetal arterial PO2 values decline, whereas arterial pH remains unchanged, and hematocrit increases to maintain O2 delivery (16). Hypoxic fetal weights increase during gestation, and near-term fetal weights are comparable to control fetuses maintained at 718 m. Fetal morbidity, mortality, and abortion do not increase in this model. Animals in the present study were exposed to the same degree of hypoxic stress as in our laboratory's previous studies, with arterial PO2 values similar to previously published values in both age groups (3, 4, 20, 21). Overall, the high-altitude model we employed in these studies represents moderate chronic hypoxia, enabling adaptive responses to be studied.
Function of adrenergic and nNOS nerves. Activation of perivascular nerves in MCAs from normoxic fetal and adult sheep caused a significant increase in both NE and NO overflow compared with the respective basal overflows. Stimulation-evoked NE and NO release were antagonized by the neurotoxin TTX, confirming a neuronal source of both substances. Furthermore, in MCAs from normoxic fetal and adult sheep, stimulation-evoked NE release was antagonized by the NOS inhibitor L-NAME, an effect reversed by the NO donor SNAP. These data confirm that cerebrovascular arteries are unique, containing both adrenergic and nNOS neurons, and that NE release is facilitated by NO. The conclusions derived from the MCAs are strengthened by studies of our comparison model, the facial artery. Electrical stimulation has been previously shown to increase NE release in the facial artery of adult animals, but there is no increase in NO overflow and no effect of L-NAME on NE release (4, 24). In the present study, we confirm and extend these results showing a similar lack of nNOS function in facial arteries from the normoxic fetal sheep. Overall, the present data are in agreement with our previous studies suggesting that MCAs contain both adrenergic and nNOS nerves (4, 24). In addition, these data are consistent with other studies suggesting that cerebral vessels contain nNOS neurons (19, 29, 33, 39).
Given the close proximity of adrenergic and nNOS nerves, functional interactions between these nerves have been a topic of interest (18, 28). In rat atria mesenteric arteries and cerebral cortex and in sheep MCAs, stimulation-evoked NE release is inhibited by NOS antagonists (4, 13, 24, 25, 37, 38). These studies suggest that NO from nNOS nerves serves to augment adrenergic nerve activity. Indeed, our present study shows that, in both normoxic fetal and adult MCAs, L-NAME significantly inhibits stimulation-evoked NE release. These results demonstrate the facilitatory effect of NO on adrenergic nerve activity in the cerebral vasculature. The mechanism underlying this facilitatory effect of NO is unclear, but studies have begun to illuminate this process. In superior cervical ganglion cells, NO donors such as SNAP increase calcium current amplitude, whereas in PC12 cells NO donors have been shown to increase the sensitivity of intracellular calcium release mechanisms to calcium (7, 9). These effects are mimicked by the cGMP analog 8-bromo-cGMP, suggesting that NO signaling through the cGMP pathway may elevate stimulation-evoked increases in intracellular calcium. This provides at least one explanation for the ability of NO to augment stimulation-evoked NE release.Hypoxia and nNOS in cerebral arteries. In complete contrast to MCAs from normoxic sheep, stimulation-evoked NO release as well as the effect of L-NAME were selectively abolished in MCAs from hypoxic fetal and adult sheep. These data are consistent with our laboratory's previous study demonstrating that the effect of L-NAME to depress stimulation-evoked NE release in adult and fetal MCAs is abolished with chronic hypoxia (4). Despite a decline in function of facilitatory nNOS nerves after hypoxic acclimatization, stimulation-evoked NE release was not significantly altered in fetal or adult MCAs (Fig. 2). NE content in both fetal and adult MCAs declined during chronic hypoxia (Table 3); despite this decline, NE release was maintained. These data suggest that adrenergic nerves in fetal and adult cerebral arteries may compensate for hypoxic declines in function of nNOS nerves and NE content to maintain their overall function. Further studies are necessary to define the mechanisms underlying sustained adrenergic nerve function during chronic hypoxia.
To further our understanding of the impact of chronic hypoxia at high altitude, we measured the relative abundance of nNOS in cerebral arteries in fetal and adult sheep and expressed stimulation-evoked NO overflow as a fraction of total soluble protein. We found that the abundance of nNOS in cerebral arteries dramatically declined after high-altitude chronic hypoxia in both the fetus and adult. Consistent with these data, stimulation-evoked NO release as a fraction of soluble protein also declined, and there was no significant difference between hypoxic fetus and adult. These data suggest that at least one mechanism for the decline in NO release and the corresponding loss of the effect of L-NAME on stimulation-evoked NE release is the marked decline in the levels of perivascular nNOS. To our knowledge, this is the first study to report such results. In normoxic animals, the relative abundance of nNOS was similar in fetal and adult cerebral arteries. Second, stimulation-evoked NO release as a fraction of total soluble protein was also similar in fetal and adult cerebral arteries. Thus, although total stimulation-evoked NO overflow in fetal was lower than adult MCAs, when corrected for total soluble protein content stimulation-evoked NO release was similar in the fetus and adult. These data contrast a previous study demonstrating that maximal nNOS activity is greater in the brain of adult rats compared with 14- to 18-day-old pups (26). This study, carried out in the presence of saturating levels of cofactors, suggested that a change in the function of NO with development could be due in part to changes in cerebral nNOS levels during prenatal and early postnatal life. Consistent with this idea, it has been shown that hormones known to change during pregnancy and development affect nNOS levels in the rat brain (12). However, the study of Pearce et al. (26) focused on brain parenchyma, which is undergoing rapid growth and development, whereas our study focuses on vascular innervation, which might have a very different timetable for developmental patterns of protein expression. Overall, the present study suggests that mechanisms controlling cerebrovascular nNOS protein levels appear to be near or fully developed in the near term fetus.Effect of development on NE release. There is little information on the impact of development specifically on stimulation-evoked fractional NE release. In this study, both basal and stimulation-evoked fractional NE release from MCAs were significantly greater in the fetus than in the adult. Thus, during development, adrenergic nerve function appears to decline. The data in this study are consistent with our laboratory's previous studies suggesting that adrenergic nerve activity rises just before birth (3, 4). Moreover, the data are consistent with rising plasma levels of NE in both rats and sheep (8, 31). The rise in sympathetic nerve activity before birth suggests that the fetus must prepare to transition from a highly modulated environment to the external environment where multiple vascular mechanisms become essential for homeostasis (27).
In conclusion, we have shown that nNOS nerves augment stimulation-evoked NE release in cerebral vessels of both adult and fetal sheep. Furthermore, we confirm that both our initial hypotheses are correct: 1) acclimatization to chronic high-altitude hypoxia during gestation markedly attenuates the function of nNOS nerves and 2) high-altitude hypoxia drastically reduces nNOS abundance in cerebral arteries. Despite the loss of nNOS nerve function, adrenergic nerves maintain their activity, supporting successful adaptation to high-altitude hypoxia. Our study demonstrates that at least one mechanism underlying the decline in nNOS nerve function is a significant decline in nNOS levels during chronic hypoxia. Although in our study successful adaptation to high-altitude hypoxia appears to have occurred, the loss of function of nNOS nerves may still have consequences for the distribution of cerebral blood flow during acclimatization at high altitude.| |
ACKNOWLEDGEMENTS |
|---|
This work was supported in part by National Institute of Child Health and Human Development Grant P01-HD-31226, American Heart Association National Affiliate Established Investigator Award 0040021N, and National Heart, Lung, and Blood Institute Grant RO1-HL-50775.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: J. Buchholz, Dept. Physiology and Pharmacology, Loma Linda Univ., School of Medicine, Loma Linda, CA 92350 (E-mail: jbuchholz{at}som.llu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published October 25, 2002;10.1152/japplphysiol.00771.2002
Received 23 August 2002; accepted in final form 23 October 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bill, A,
and
Linder J.
Sympathetic control of cerebral blood flow in acute arterial hypertension.
Acta Physiol Scand
96:
114-112,
1976[Web of Science][Medline].
2.
Buchholz, J,
and
Duckles SP.
In vitro measurement of endogenous norepinephrine release from small blood vessels with short stimulation trains.
J Pharmacol Toxicol Methods
28:
137-141,
1992[Web of Science][Medline].
3.
Buchholz, J,
and
Duckles SP.
Chronic hypoxia alters prejunctional
2-adrenoceptor function in vascular adrenergic nerves of adult and fetal sheep.
Am J Physiol Regul Integr Comp Physiol
281:
R926-R934,
2001
4.
Buchholz, J,
Teunissen KE,
and
Duckles SP.
Impact of development and chronic hypoxia on NE release from adrenergic nerves in sheep arteries.
Am J Physiol Regul Integr Comp Physiol
276:
R799-R808,
1999
5.
Busija, DW,
and
Heistad DD.
Factors involved in the physiological regulation of cerebral circulation.
Rev Physiol Biochem Pharmacol
101:
161-211,
1984[Web of Science][Medline].
6.
Busija, DW,
Heistad DD,
and
Marcus ML.
Effects of sympathetic nerves on cerebral vessels during acute, moderate increases in arterial pressure in dogs and cats.
Circ Res
46:
696-702,
1980
7.
Chen, C,
and
Schofield GG.
Nitric oxide donors enhanced Ca2+ currents and blocked noradrenaline-induced Ca2+ current inhibition in rat sympathetic neurons.
J Physiol
482:
521-531,
1995
8.
Choi, S,
Weisenberg SN,
and
Kellogg CK.
Control of endogenous norepinephrine release in the hypothalmus of male rats changes over adolescent development.
Brain Res Dev Brain Res
98:
134-141,
1997[Medline].
9.
Clementi, E,
Riccio M,
Sciorati C,
Nistico G,
and
Meldolesi J.
The type 2 ryanodine receptor of neurosecretory PC12 cells is activated by cyclic ADP-ribose.
J Biol Chem
271:
17739-17745,
1996
10.
Dun, NJ,
Dun SL,
Chiba T,
and
Forstermann U.
Nitric oxide synthase-immunoreactive vagal afferents in rat superior cervical ganglia.
Neuroscience
65:
231-239,
1995[Web of Science][Medline].
11.
Faucher, DJ,
Laptook AR,
Porter JC,
and
Rosenfeld CR.
Effects of acute hypercapnia on maternal and fetal vasopressin and catecholamine release.
Pediatr Res
30:
368-374,
1991[Web of Science][Medline].
12.
Forsterman, U,
and
Kleinhart H.
Nitric oxide synthase: expression and expressional control of the three isoforms.
Naunyn Schmiedebergs Arch Pharmacol
342:
351-364,
1995.
13.
Gironacci, MM,
Lorenzo PS,
and
Graschinsky EA.
Possible participation of nitric oxide in the increase of norepinephrine release caused by angiotensin peptides in rat atria.
Hypertension
29:
1344-1356,
1997
14.
Gleed, RD,
Poore ER,
Figueroa JP,
and
Nathanielsz PW.
Modification of maternal and fetal oxygenation with the use of tracheal gas infusion.
Am J Obstet Gynecol
155:
429-435,
1986[Web of Science][Medline].
15.
Heistad, DD,
and
Marcus ML.
Effect of sympathetic stimulation on permeability of the blood-brain barrier to albumin during acute hypertension in cats.
Circ Res
45:
331-338,
1979
16.
Kamitomo, M,
Longo LD,
and
Gilbert RD.
Right and left ventricular function in fetal sheep exposed to long-term high-altitude hypoxemia.
Am J Physiol Heart Circ Physiol
262:
H399-H405,
1992
17.
Lambertsen, CJ.
Anoxia, altitude, and acclimatization.
In: Medical Physiology. St. Louis, MO: Mosby, 1968, p. 810-835.
18.
Lee, TJF,
and
Sarwinski S.
Nitric oxidergic neurogenic vasodilation in the porcine basilar artery.
Blood Vessels
28:
407-412,
1991[Web of Science][Medline].
19.
Lee, TJF,
Zhang W,
and
Sarwinski S.
Pre-synaptic
2-adrenoceptors mediate nicotine-induced NOergic neurogenic dilation in porcine basilar arteries.
Am J Physiol Heart Circ Physiol
279:
H808-H816,
2000
20.
Longo, LD,
Long DM,
and
Pearce WJ.
Cerebrovascular adaptations to high-altitude hypoxemia in fetal and adult sheep.
Am J Physiol Regul Integr Comp Physiol
264:
R65-R72,
1993
21.
Longo, LD,
and
Pearce WJ.
High altitude, hypoxic-induced modulation of noradrenergic-mediated responses in fetal and adult cerebral arteries.
Comp Biochem Physiol A Mol Integr Physiol.
119:
683-694,
1998[Medline].
22.
Lorjin, RHW,
and
Longo LD.
Norepinephrine elevation in the fetal lamb: oxygen consumption and cardiac output.
Am J Physiol Regul Integr Comp Physiol
239:
R115-R122,
1980
23.
Martire, M,
Altobelli D,
Cannizzaro C,
and
Preziosi P.
Effects of nitric oxide donors on basal and K+-evoked release of [3H]noradrenaline from rat cerebral cortex synaptosomes.
Eur J Pharmacol
350:
345-351,
1998[Web of Science][Medline].
24.
Mbaku, EN,
Zhang L,
Duckles SP,
and
Buchholz JN.
Nitric oxide synthase-containing nerves facilitate adrenergic transmitter release in sheep middle cerebral arteries.
J Pharmacol Exp Ther
293:
397-402,
2000
25.
Montague, PR,
Gancayco CD,
Winn MJ,
Marchase RB,
and
Friedlander MJ.
Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex.
Science
263:
973-977,
1994
26.
Pearce, WJ,
Tone B,
and
Ashwal S.
Maturation alters cerebral NOS kinetics in the spontaneously hypertensive rat.
Am J Physiol Regul Integr Comp Physiol
273:
R1367-R1373,
1997
27.
Phillippe, M.
Fetal catecholamines.
Am J Obstet Gynecol
146:
840-855,
1983[Web of Science][Medline].
28.
Rose, CE, Jr,
Althaus JA,
Kaiser DL,
Miller ED,
and
Carey RM.
Acute hypoxemia and hypercapnia: increase plasma catecholamines in conscious dogs.
Am J Physiol Heart Circ Physiol
245:
H924-H929,
1983
29.
Si, ML,
and
Lee TJF
Presynaptic
7-nicotinic acetylcholine receptors mediate nicotine-induced nitric oxidergic neurogenic vasodilation in porcine basilar arteries.
J Pharmacol Exp Ther
298:
122-128,
2001
30.
Smith, PK,
Krohn RI,
Hermanson GT,
Mallia AK,
Gartner FH,
Provenzano MD,
Fujimoto EK,
Goeke NM,
Olson BJ,
and
Klenk D.
Measurement of protein using bicinchoninic acid.
Anal Biochem
150:
76-85,
1985[Web of Science][Medline].
31.
Smolich, JJ,
Cox HS,
Eisenhofer G,
and
Esler MD.
Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs.
Am J Physiol Lung Cell Mol Physiol
273:
L264-L274,
1997
32.
Toda, N,
and
Okamura T.
Possible role of nitric oxide in transmitting information from vasodilator nerve to cerebroarterial muscle.
Biochem Biophys Res Commun
170:
308-313,
1990[Web of Science][Medline].
33.
Toda, N,
and
Okamura T.
Role of nitric oxide in neurally induced cerebroarterial relaxation.
J Pharmacol Exp Ther
258:
1027-1032,
1991
34.
Tracey, WR,
Pollock JS,
Murad F,
Nakane M,
and
Forstermann U.
Identification of an endothelial-like type III NO synthase in LLC-PK1 kidney epithelial cells.
Am J Physiol Cell Physiol
266:
C22-C28,
1994
35.
Wu, SY,
Dun SL,
Forstermann U,
and
Dun NJ.
Nitric oxide and excitatory postsynaptic currents in immature rat sympathetic preganglionic neurons in vitro.
Neuroscience
79:
237-245,
1997[Web of Science][Medline].
36.
Xiao, D,
Liu Y,
Pearce WJ,
and
Zhang L.
Endothelial nitric oxide release in isolated perfused ovine uterine arteries: effect of pregnancy.
Eur J Pharmacol
367:
223-230,
1999[Web of Science][Medline].
37.
Yamamoto, R,
Wada A,
Asada Y,
Niina H,
and
Sumiyoshi Y.
N
-nitro-L-arginine, an inhibitor of nitric oxide synthesis, decreases noradrenaline outflow in rat isolated perfused mesenteric vasculature.
Naunyn Schmiedebergs Arch Pharmacol
347:
238-240,
1993[Web of Science][Medline].
38.
Yamamoto, R,
Wada A,
Asada Y,
Toshihiko Y,
Tomoaki Y,
Niina H,
Sumiyoshi A,
Kobayashi H,
and
Lee TJF
Nitric oxide-dependent and -independent norepinephrine release in rat mesenteric arteries.
Am J Physiol Heart Circ Physiol
272:
H207-H210,
1997
39.
Zhang, W,
Edvinsson L,
and
Lee TJF
Mechanism of nicotine induced relaxation in the porcine basilar artery.
J Pharmacol Exp Ther
284:
790-797,
1998[Abstract].
This article has been cited by other articles:
![]() |
W. J. Pearce, J. M. Williams, C. R. White, and T. M. Lincoln Effects of chronic hypoxia on soluble guanylate cyclase activity in fetal and adult ovine cerebral arteries J Appl Physiol, July 1, 2009; 107(1): 192 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Pena, T. Tomimatsu, D. P. Hatran, L. L. McGill, and L. D. Longo Cerebral blood flow and oxygenation in ovine fetus: responses to superimposed hypoxia at both low and high altitude J. Physiol., January 1, 2007; 578(1): 359 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Vanterpool, E. A. Vanterpool, W. J. Pearce, and J. N. Buchholz Advancing age alters the expression of the ryanodine receptor 3 isoform in adult rat superior cervical ganglia J Appl Physiol, August 1, 2006; 101(2): 392 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Pearce Hypoxic regulation of the fetal cerebral circulation J Appl Physiol, February 1, 2006; 100(2): 731 - 738. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J Norcliffe, M Rivera-Ch, V. E Claydon, J. P Moore, F Leon-Velarde, O Appenzeller, and R Hainsworth Cerebrovascular responses to hypoxia and hypocapnia in high-altitude dwellers J. Physiol., July 1, 2005; 566(1): 287 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Longo and W. J. Pearce Fetal cerebrovascular acclimatization responses to high-altitude, long-term hypoxia: a model for prenatal programming of adult disease? Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2005; 288(1): R16 - R24. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |